• 00D
  • 00H
  • 00M
  • 00S

Partners

The 2024 ANZCHOG Annual Scientific Meeting is the premier event for the Australia and New Zealand Children’s Haematology/ Oncology Group. Bringing together more than 250 members of the industry including paediatric oncologists, haematologists, nurses, allied and mental health professionals, research scientists, clinical research professionals, and parents, to discuss the latest developments in research and treatment. 

The event will cover the latest in research and development and industry news. Don’t miss the opportunity to be part of that conversation! 

Applications for partnership

Show your support for the Annual Scientific Meeting 2024 by becoming a partner or exhibitor. 

For all partnership or exhibition enquiries, please contact:

c/o MCI Australia 

Rebecca Teuma
ANZCHOG ASM Partnership Manager 

Principal Conference Partner
Diamond Partner
Gold Partner
Silver Partner
International Speaker Partner
Program Partner
Grant Partner
Destination Partner
Exhibitors
Principal Conference Partner
Gold Sponsor
Silver Sponsor
International Speaker Partner
Program Partner
Meeting App Partner
Destination Partner
Exhibitors

At Recordati Rare Diseases, we focus on the few – those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. Patients with rare diseases are our top priority. They are at the core of our planning, our thinking and our actions.

Recordati Rare Diseases is a pharmaceutical company that provides treatment for patients with rare diseases. Created in 1990, Recordati Rare Diseases is one of the most active companies in the field of rare diseases.

Our speciality rate disease products are marketed directly by Recordati Rare Diseases in Europe, the Middle East, the U.S.A, Canada, Russia, Japan and Australia, in some Latin American countries, and through selected partners in other parts of the world.

Minderoo Foundation takes on tough, persistent issues with the potential to drive massive change.

Andrew and Nicola Forrest founded Minderoo Foundation in 2001, and continue to drive its philanthropic mission today.

We incubate ideas, advocate for systems change and accelerate impact. We push the limits of what is believed possible.

Minderoo Foundation is proudly Australian, independent, forward thinking and seeks effective, scalable solutions.

Through bold, collaborative and selfless action, we must dismantle the systems that entrench inequality.

Together we collaborate, advocate, innovate, fight and act for a fairer future.

Bayer is a global life science company with expertise in healthcare and agriculture. The company has had a presence in Australia since 1925 and has a long-term commitment to the health and nutrition of all Australians and New Zealanders. As people live longer and the population continues to grow both locally and beyond, Bayer is one of the few companies that takes a comprehensive view of these issues. Guided by our purpose – Science for a better life – we apply our global scientific expertise in healthcare and agriculture to deliver innovations locally to help people and the planet thrive.

Bayer employs almost 900 people across Australia and New Zealand and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees’ unique identities and advances a culture of inclusion and diversity across gender, LGBTQIA+, generations, disability and race.

For further information visit www.bayer.com.au

Alexion, Astra Zeneca Rare Diseases, has been a leader in rare diseases for 30 years. Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialisation of life-changing medicines. We work alongside healthcare providers, patient advocacy organisations and governments to best serve patients by innovating and expanding our knowledge of rare diseases. Our goal is to bring hope to patients and families by delivering scientific advances

At Jazz Pharmaceuticals plc (NASDAQ: JAZZ), our purpose is to innovate to transform the lives of patients and their families.

We are focused on developing life-changing medicines for people with serious diseases — often with limited or no options — so they can live their lives more fully. By transforming biopharmaceutical discoveries into novel medicines, we are working to give people around the world the opportunity to redefine what’s possible – to make the “small wins” big again.

We are a fully integrated, global biopharmaceutical company with a diverse portfolio of marketed medicines and novel product candidates for adults and children, and expertise in two key therapeutic areas: neuroscience and oncology. We are an industry leader in treating sleep disorders and epilepsy, and in oncology we are investigating and delivering medicines for hard-to-treat hematologic malignancies and solid tumors. We use our deep knowledge of and commitment to these fields to innovate and identify new solutions where none previously existed.

RUN DIPG is a charity dedicated to improving outcomes for patients, families and communities impacted by the deadliest form of childhood cancer – the brainstem cancer, diffuse intrinsic pontine glioma (DIPG), also known as diffuse midline glioma (DMG). We are committed to achieving this by raising awareness, empowering advocates and fundraising to support DMG/DIPG research. 

We’re all about changing the odds of paediatric brain cancer, to make brain tumours go the way of the dinosaurs. This is why we we fund brain projects in the areas of research, care and development – to fund the science to end brain cancer and support patients in the meantime.

The Pirate Ship Foundation is a community that funds vital research into childhood brain cancer through a range of initiatives, adventures, events and partnerships.

Funds are invested directly into childhood brain cancer research programs, including to the Brain Tumour Research Program at Telethon Kids Institute in Perth.

Support from the Foundation has seen brain cancer research at Telethon Kids Institute expand from one individual in 2008, to the establishment of a dedicated Brain Tumour Research team of 20 within the Telethon Kids Cancer Centre.

This world-renowned laboratory is the largest of its kind in the Southern Hemisphere and is a key part of the international network of collaborating institutes.

The Foundation currently funds two Fellowships at TKI, with the aim of finding improved treatments and ultimately a cure for childhood brain cancer.

The Foundation is proud that around 90% of funds raised are available for research.

The creation of the Foundation was inspired by nine year old Jennifer Harper, who was diagnosed with leukaemia in 1977. When her father, Peter Harper, discovered that there was no research into children’s leukaemia being done in Western Australia, he set out, together with other parents of children with cancer, to raise funds for this purpose. Sadly Jennifer passed away in 1978.

The quest to find cures for childhood cancer is one of medicine’s greatest success stories. Fifty years ago only two percent of children with cancer survived. Medical research alone has improved overall survival rates to 80 percent. With childhood cancer still the leading cause of death from disease in Australian children, there is more work to be done. There are still particular childhood cancers – such as brain tumours and neuroblastoma — with survival rates as low as 50 percent.

CCRF has a commitment to ensure this ground-breaking research continues so that the future generations will be the ones to live cancer free. The Foundation relies on the generous support of the community to continue its vital research, as we do not receive State or Federal funding.

The Kids’ Cancer Project is an independent national charity supporting childhood cancer research. Since 1993, thanks to strong community support, the charity has contributed tens of millions of dollars to scientific research projects to help children with many types of cancer.

Founder, Col Reynolds OAM, has a steely focus to make a difference to the lives of kids living with cancer. It all started on an ordinary day in the late 1980s when the bus driver was driving his empty tourist coach past the Children’s Hospital in Camperdown, Sydney. After stopping to let two youngsters with bald heads cross the road, he parked his vehicle and went into the hospital on the spur of the moment. Touched by the spirit of everyone he met that day, Col made it his personal mission to help kids with cancer in any way he could. Very early in his quest, he learned the only way to improve outcomes for these children would be through advances in medical research.

Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine.

We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of paediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of our ambitions.

Scientific discoveries don’t happen overnight or without hard work. But our determination to find answers for patients motivates us to develop breakthrough medicines and vaccines. And to never settle.

Learn more at sanofi.com.au

BD is a global medical technology company that is advancing the world of health™ by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures and support the management of diabetes.

Becton Dickinson Pty. Ltd., an Australian subsidiary company, commenced operations in Melbourne in 1981. In October 1996, Becton Dickinson Limited (New Zealand) was established to demonstrate the company’s total commitment to servicing both the Australian and New Zealand markets. BD has a strong presence across its three core businesses in Australia and New Zealand with its Head Office in Sydney and with offices in Auckland, Melbourne, Brisbane, Perth and Adelaide.

REM SYSTEMS understands that healthcare workers’ safety is as important as patient safety, particularly when working with hazardous drugs. Our wide range of quality products is carefully selected to meet the needs of clinicians working within this specialist area. REM SYSTEMS offers a range of products specific to hazardous drug compounding both in the pharmacy and on the ward.

Hazardous drug compounding and delivery is our specialty, and our range provides additional levels of protection when working with hazardous drugs.

1800-737-222 customerservice@remsystems.com.au www.remsystems.com.au

The Cancer Institute NSW is committed to lessening the impact of cancer in NSW.

The Institute works with the community, people affected by cancer, health professionals, researchers, governments and charity organisations to:

  • provide information and advice about preventing cancer, including iCanQuit for smoking cessation and skin cancer-focused campaigns such a Pretty Shady.
  • promote the importance of early detection via services like BreastScreen NSW, cervical and bowel screening.
  • provide grants that foster innovation in cancer research, with a focus on translational research
  • maintain quality information and data about cancer in NSW
  • support and promote best practice; to ensure people across the state, no matter where they live, are provided the same high-quality treatment and care
  • provide health professionals with resources for cancer treatment online via EviQ.
* indicates required